Therapeutic Silencing of MicroRNA-33 Inhibits the Progression of Atherosclerosis in Ldlr−/− Mice—Brief Report
N Rotllan, CM Ramírez, B Aryal, CC Esau… - … , and vascular biology, 2013 - Am Heart Assoc
N Rotllan, CM Ramírez, B Aryal, CC Esau, C Fernández-Hernando
Arteriosclerosis, thrombosis, and vascular biology, 2013•Am Heart AssocObjective—To study the efficacy of anti–miRNA-33 therapy on the progression of
atherosclerosis. Approach and Results—Ldlr−/− mice were injected subcutaneously with
PBS, control, or anti–miR-33 oligonucleotides weekly and fed a Western diet for 12 weeks.
At the end of treatment, the expression of miR-33 target genes was increased in the liver and
aorta, demonstrating effective inhibition of miR-33 function. Interestingly, plasma high-
density lipoprotein (HDL)-cholesterol was significantly increased in anti–miR-33-treated …
atherosclerosis. Approach and Results—Ldlr−/− mice were injected subcutaneously with
PBS, control, or anti–miR-33 oligonucleotides weekly and fed a Western diet for 12 weeks.
At the end of treatment, the expression of miR-33 target genes was increased in the liver and
aorta, demonstrating effective inhibition of miR-33 function. Interestingly, plasma high-
density lipoprotein (HDL)-cholesterol was significantly increased in anti–miR-33-treated …
Objective
To study the efficacy of anti–miRNA-33 therapy on the progression of atherosclerosis.
Approach and Results
Ldlr−/− mice were injected subcutaneously with PBS, control, or anti–miR-33 oligonucleotides weekly and fed a Western diet for 12 weeks. At the end of treatment, the expression of miR-33 target genes was increased in the liver and aorta, demonstrating effective inhibition of miR-33 function. Interestingly, plasma high-density lipoprotein (HDL)-cholesterol was significantly increased in anti–miR-33-treated mice but only when they were fed a chow diet. However, HDL isolated from anti–miR-33-treated mice showed an increase cholesterol efflux capacity compared with HDL isolated from nontargeting oligonucleotide-treated mice. Analysis of atherosclerosis revealed a significant reduction of plaque size and macrophage content in mice receiving anti–miR-33. In contrast, no differences in collagen content and necrotic areas were observed among the 3 groups.
Conclusions
Long-term anti–miR-33 therapy significantly reduces the progression of atherosclerosis and improves HDL functionality. The antiatherogenic effect is independent of plasma HDL-cholesterol levels.
Am Heart Assoc